As Genentech is celebrating its 40th Birthday, it is also the 40th birthday of Biotechnology and the 40th birthday of Biotech Venture Capitalists.

biotech_finance_investor_vcThese risk investors are deeply linked to any venture successes. And although Europe definitely has fewer than in the US, there’s still a significant amount of influence and wealth on this side of the Atlantic.

Note: I’ve only listed non-corporate investors and only VCs having their ‘headquarters’ in Europe.

The investors are in no particular order as it’s hard to find one common criteria, wether it is money under management, number of investments, return on investment, team size or any other criteria.

So here’s our list of 18 top-Europe Biotech VCs!


Woodford – The British Biotech Super-investor 

woodford_logo

Location: London (UK)

Foundation: 2014

Money under management: Last fund €1.1Bn on 04/2015 – investment public and private Biotech companies

Managing partner:

neil_woodford_biotech_finance_investor_vc_europe

Neil Woodford

Portfolio & exited companies:woodford_portofolio

Comment: Neil Woodford is one the most respected British fund managers. His 30 years of experience has been  re-injected into the fund to assure returns on the massive amount of money he’s raised. It’s simple: it’s the biggest UK fund ever made, whatever field we consider. And as of december 2015, he had already re-invested 75% of the money, mostly into British/European Biotechs.


LSP – One of the most successful VCs in Europe

logo_lsp

Location: Amsterdam (Netherlands)

Foundation: 1988

Money under management: Over €1Bn – last undisclosed investment from BMS in 2015

Managing partner:

LSP_life_Science_partners_vc_europe_biotech_finance

Martijn Kleijwegt

Portfolio & exited companies:

lsp_portfolio

Comment: LSP is one of the oldest and most successful Biotech investors in Europe. It claims over 25% return on investment per year in private investment, which is very high. To get to this high return, it participated in many of the European success stories, such as Qiagen, Crucell and more recently ProSensa, sold $840M to BioMarin early 2015.


Sofinnova – “Le” French VC

sofinnovapartnersLocation: Paris, France

Foundation: 1972

Money under management: €1.5Bn – Last fund €300M 12/2015

Managing partner:

sofinnova_biotech_vc_fund

Denis Lucquin

Portfolio & exited companies:sofinnova_portofolio

Comment: Sofinnova is French largest VC company and probably one of the oldest in Europe. It invested in several great success-story, such as Actelion (Switzerland), DBV (France) and Stentys (France).

It has some portfolio companies in France, but its focus is pan-european. I met Denis Lucquin 3 years ago during our Labiotech ‘Tour de France and I was really impressed by his large experience and his vision of the European biotech ecosystem.


Medicxi – the Spin-out of Index Ventures 

medicxi_ventures_logo

Location: London (UK)

Foundation: 2016

Last round: €210M closed 02/2016

Managing partner:

medixci_ventures_vc_europe_biotech

Francesco De Rubertis

Portfolio & exited companiesmedicxi_ventures_portfolio medicxi_ventures_portfolio

Comment: This is the most ‘recent’ VC of the list. Medicxi was formerly the life science branch of Index Ventures, the overly successful Internet investor. De Rubertis founded the life science branch in 1997.

Now, the first round of Medicxi is massive (€210M) and the management team has plenty of experience. It will be interesting to follow where it is investing in in the coming months.


TVM – “das Deutsche” VC

tvm_capital_biotech_finance_vc_europe
Location: Munich (Germany)

Foundation: 1984

Money under management: €900M –  Last fund TVM VII €175M ($201.6M) 10/2014

Managing partner:

tvm_biotech_investor_finance_europe_vc_top

Helmut Schühsler

Portfolio & exited companies:

tvm_portofolio

Comment: TVM (Life Science Venture Capital) is the oldest German Biotech VC company. It’s pretty much invested in all German Biotech success-stories – QiagenDirevo, Jerini, Morphosys, Evotec, etc.

Ultimately, it has played an essential role in building up the German Biotech ecosystem, to the N°1 in Europe in terms of companies and people employed.


Abingworth – UK’s oldest Biotech fund  

logo_abingworthLocation: London (UK)

Foundation: 1973

Money under management: Over €1Bn – last fund €90M ($105M) on 01/2016

Managing partner:

Tim-Haines_abingworthTim Haines

Portfolio & exited companies:

abingworth_portofolioComment: Abingworth is way older than me and is from the same generation as Sofinnova. Their last fund, Abingworth Bioventures VI, is theoretically the 6th (or the 9th if we count several rounds for the same fund).

Having so many funds under management is a good sign of success for a VC, and the Bioventures VI is already on a good track. CRISPR Therapeutics (Switzerland) to name only one of their portfolio companies, is the biggest CRISPR company in Europe and could play a key role in the industrialization of this revolutionary gene editing technology.

P.S. A partner of Abingworth will be at Labiotech Refresh on May 24th in Berlin


Wellington – TVM’s neighbour

wellington_partners_logo

Location: Munich (Germany)

Foundation: 1998

Money under management: €850M

Managing partner:

wellington_partners_biotech_investor_finance_vc_europe_top

Rolf Christof Dienst

Portfolio & exited companies:

wellington_portofolio

Comment: Wellington is the second big VC of Bavaria, sitting next to its neighbor TVM. It has been successful over the last 17 years, by investing in companies such as Actelion, Medigene or mtm laboratories (which was acquired for €190M by Roche in 2011). Some more recent highlights include the exit of MedImmune/AstraZeneca for €130M ($150M) in 2014 and the acquisition of Sapiens by Medtronic for €175M ($200M) in 2014 as well.


HBM Healthcare Investments – the leading Swiss Biotech investor 

hbm bioventures

Location: Zug (Switzerland – and the Cayman Islands)

Foundation: 2001

Money under management: €775M (846M CHF)

Managing partner:

HBM_biotech_investor_europe_vc_top

Hans Peter Hasler

Portfolio & exited companies:

probiodrug_biotech_investor_VC_finance_europe_nabriva_curetis

Comment: Surprisingly, HBM is publicly listed on the Swiss Stock Exchange. It seems to have done well in the past few years, having many successful companies in their portfolio.

Nabriva is an Austrian Biotech which just raised $100M on the NASDAQ and that could be a good return on investment for HBM.


Sunstone – the Largest independent Scandinavian VC

logo_sunstone_capital

Location: Copenhagen (Denmark)

Foundation: 2007

Money under management: €700M

Managing partner:

sunstone_biotech_life_sciences_finance_vc_top

Peter Benson

Portfolio & exited companies:

sunstone_portofolio

Comment: Sunstone is THE independent Life Science Venture Capitalist of Scandinavia (almost). It is the most major VC aside Novo (the huge investment arm of Novo Nordisk) or Lundbeck.

Sunstone picked up the best Nordic Biotechs, including the 3 mentioned above.


Kurma – the European Venture launcher 

kurma_pharma_vc_fund_biotech_europe_finance_top_

Location: Paris (France)

Foundation: 2009

Money under management: €239M – last fund Kurma Diagnostics of €33M in May 2015

Managing partner:

kurma_pharma_biotech_finance_europe_vc_investor

Thierry Laugel

Portfolio & exited companies:

kurma_portfolio

Comment: Kurma can be seen as a ‘mini’ Flagship Ventures, the famous Boston-based investor (interview here), which co-founded some major companies like Moderna, Editas and Agios.

Flagship, of course, manages way more cash than Kurma, but the model of Kurma is similar. It co-founds companies from scratch by taking an innovation from University, accelerating its development and ultimately leading to an exit or an IPO.


Forbion Partners – a leading Dutch VC

forbion-logo-home

Location: Naarden – next to Amsterdam (Netherlands)

Foundation: 2000

Money under management: €700M – last fund €175M ($200M) today

Managing partner:

sander_slootweg_forbion_partners_biotech_finance_vc_fund_investor

Sander Slootweg

Portfolio & exited companies:

forbion_portofolio

Comment: The Netherlands is not the first Europe Biotech ecosystem we think of (because of the small size of the country) but it has some great examples. I was positively surprised when we selected companies for our map.

I believe Forbion played an important role in this success. It invested in the best companies the country -and its Belgian neighbor – has much to offer, as uniQure (Netherlands), Galapagos (Belgium) and argenx (also Belgium) illustrate so well.

P.S. I interviewed a partner of Forbion here on his last NASH investment.


Seventure – The Microbiome Specialist

logo_seventureLocation: Paris (France)

Foundation: 1997

Money under management: €600M – last fund €160M in 12/2015

Managing partner:

seventure_biotech_investor_finance_europe_

Isabelle de Cremoux

Portfolio & exited companies:

seventure_portofolio

Comment: Seventure has invested in Life Sciences since 1998, with successful exits such as Santaris (sold to Roche €450M in August 2014).

More interestingly, Seventure is a strong believer in the development of Microbiome research. It created the World-first €160M investment fund dedicated to this new and promising field. First investments includes Enterome and Eligo Bioscience (both France) two of the most promising Microbiome French startups.

Ps: De Cremoux and Eligo Biosciences’ CEO will be at Labiotech Refresh in Berlin on May 24th. You should come of you wanna meet them! 😉


Dievini – the Biotech investment arm of Dietmar Hopp (the European Bill Gates, founder of SAP)

dievini_biotech_investor_finance_europe_top

Location: Walldorf (Germany) (next to Heidelberg/Mannheim)

Foundation: 2005

Money under management: +- €900M

Managing partner:

dievini_biotech_germany_europe_investor_top_vc

Friedrich von Bohlen

Portfolio & exited companies:

dievini_portofolio

Comment: Dievini is one of the largest venture capitalists in Germany. It was founded with a part of the fortune of Dietmar Hopp, the famous founder of the software giant SAP.

Its flagship company is CureVac (Germany), the most advanced company to bring mRNA drugs on the market and challenging the cash-magnet Moderna from Boston.

PS: My partner Joachim interviewed Von Bohlen a few months ago for one of our Tour, click here to watch the video.


Truffle Capital – an Entrepreneur and Investor at the same time

truffle_capitalLocation: Paris (France)

Foundation: 2001

Money under management: €730M (Internet and Biotech)

Managing partner:

pouletty_truffle_biotech_investor_vc

Philippe Pouletty

Portfolio & exited companies:

truffle_portfolio

Comment: Truffle is well-known thanks to its iconic life science partner Philippe Pouletty. He is probably one of the biggest bio-entrepeneurs in France. His specialty? He co-founds the companies he invests in by partnering with an accomplished scientist (Miroslav Radman in the case of Deinove, Alain Carpentier in the case of Carmat etc.).

Overall, he has contributed a lot to the growth of the French Biotech ecosystem.


Malin – the Young Irish fundmalin_biotech_investor_vc_europe_tops

Location: Dublin (Ireland)

Foundation: 2015

Money under management: €330M ($380M)

Managing partner:

malin_biotech_investor_kelly_vc_europe_top_finance

Martin Kelly

Portfolio & exited companies:

malin_portofolio

Comment: Malin is a brand new Irish VC which IPO’ed this year to raise €330M. Its CEO, Martin Kelly, is one of the most well-known Biotech leaders in Ireland. He was the former CEO of Elan and has engineered a $8.6 billion sale.

The fund is obliged to invest in Ireland, as a part of the money is from the Irish Government, but it has also crossed the Irish Sea to invest 25% of the money in the UK.


Syncona – the Wellcome Trust VC Arm

syncona_logoLocation: London (UK)

Foundation: 2012

Money under management: Not disclosed – the Wellcome Trust ‘provides’ £700M per year, but not only through Syncona

Managing partner:

martin_syncona_biotech_investor_finance_europe

Martin Murphy

Portfolio & exited companies:

syncona_portofolio

Comment: Wellcome Trust is a massive foundation from the UK with an endowment of £18Bn.

It’s interesting to see it has since opened its own venture capital arm, and that all the benefits will go back to the foundation focus in Medical research.


Edmond de Rothschild Life Sciences (EDRIP) – the old family investment organization  

edmond_rothschild_life_sciences

Location: Paris,

(France)

Foundation: 2000

Money under management: €450M (specifically for life sciences)

Managing partner:

passy_edmond_de_rothschild_biotech_investor_finance_top_europe_vc

Pierre-Michel Passy

Portfolio & exited companies:

rothschild_portofolio

Comment: Edmond de Rothschild was a French member of the Rothschild banking family. Born in 1845, he helped manage the massive fortune accumulated by the Magnat family over 250 years.

Today, the group Edmond de Rothschild is active in Private Banking and Asset Management. This includes the life science branch, which is the second biggest in France judging by the amount of capital under management.


Ysios Capital – Representing Southern Europe 

logo_ysios_capital

Location: Barcelona (Spain)

Foundation: 2008

Money under management: €125M

Managing partner:

joel_mairet_ysios_capital_biotech_investor_finance_top_europe

Joël Jean-Mairet

Portfolio & exited companies:ysios_portofolio

Comment: Ysios is the leading Spanish independent VC. Its capital under management is clearly smaller than the leading European funds above, but I wanted to represent Southern Europe in this ranking.

Ysios is a young fund that already has several interesting investments, such as leading the €36.6M Serie A of Mallorcan Sanifit with Rothschild and Forbion.


This list shows clearly that Europe has (at least 18 :p) successful life science investors, which have done very well over the last few years – and are ready to invest in the next success stories.

Now, your turn to tell me. Who impresses you? Who would you have added?

P.S. I did a first “ranking” in 2015 and many friends in the venture capital business “disagreed” with the money under management I showed then. I hope it’s better this time 😉


Feature Image Credit: Edit/Remix of Open Source Graphics by Labiotech (Available under CC 3.0 Licence Labiotech.eu)
ADVERTISEMENT
Previous post

How CAR-T Cells Kill Cancer: Pictures start Moving

Next post

What sort of Biotech Startups are coming out of Italy at the moment?